Rudolf Weide

Prognostic value of end-of-induction PET response after first-line immunochemotherapy for follicular lymphoma (GALLIUM): secondary analysis of a randomised, phase 3 trial

Judith Trotman, Sally F. Barrington, David Belada et al. · The Lancet Oncology · 2018 · 159 citations · Full text

Medicine, Immunology, Oncology +13

Survival, prognostic factors and rates of leukemic transformation in 381 untreated patients with MDS and del(5q): A multicenter study

Ulrich Germing, Michael Lauseker, Barbara Hildebrandt et al. · Leukemia · 2012 · 124 citations

Medicine, Hematology, Oncology +11

Treatment and outcomes of patients in the Brain Metastases in Breast Cancer Network Registry

Isabell Witzel, Elena Laakmann, Rudolf Weide et al. · European Journal of Cancer · 2018 · 98 citations · Full text

Medicine, Oncology, Breast Oncology +16

High anti-lymphoma activity of bendamustine/mitoxantrone/rituximab in rituximab pretreated relapsed or refractory indolent lymphomas and mantle cell lymphomas. A multicenter phase II study of the German Low Grade Lymphoma Study Group (GLSG)

Rudolf Weide, H. Köppler, Jochen Heymanns et al. · Leukemia & lymphoma/Leukemia and lymphoma · 2007 · 97 citations

Medicine, Oncology, Pharmacotherapy +14

Successful long-term treatment of systemic lupus erythematosus with rituximab maintenance therapy

Rudolf Weide, Jochen Heymanns, Annette Pandorf et al. · Lupus · 2003 · 87 citations

Life Sciences, Immunology, Pharmacotherapy +13